rifaprim has been researched along with Urinary-Tract-Infections* in 2 studies
2 trial(s) available for rifaprim and Urinary-Tract-Infections
Article | Year |
---|---|
Rifaprim in urinary tract infection: a comparison with co-trimoxazole.
Two regimes of rifaprim (RPM), a 3.75 to 1 combination of rifampicin (RIF) and trimethoprim (TMP), were compared with co-trimoxazole (CO-T) for the treatment of urinary tract infection in 60 patients. Dosages were: A, 450 mg RIF + 120 mg TMP twice daily; B, 600 mg RIF + 160 mg TMP at bedtime and C, 800 mg sulphamethoxazole (SMZ) + 160 mg TMP twice daily. Clinical results were similar but CO-T treatment was accompanied by a greater number of late bacteriological failures. In none of 40 patients receiving RPM did resistance to any of the components develop, while in three of 20 patients receiving CO-T resistance to TMP or SMZ emerged during treatment. There were no side effects in the patients receiving RPM, but three patients developed transient laboratory abnormalities. One patient receiving CO-T had a rash and one further transient laboratory abnormalities. Satisfactory concentrations of RIF and TMP were measured in urine up to 24 h after a dose of 600 mg RIF + 160 mg TMP. RIF may be a better companion to TMP than the sulphonamides for the treatment of urinary tract infection. Topics: Adult; Drug Combinations; Female; Humans; Male; Middle Aged; Rifampin; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 1983 |
Controlled clinical trial of a rifampicin- trimethoprim combination (Rifaprim) and cotrimoxazole in patients with chronic urinary tract infections.
A controlled clinical trial of Rifaprim (rifampicin 600 mg plus trimethoprim 160 mg, in a single daily dose at 10 p.m.) and cotrimoxazole (two tablets b.i.d.) was carried out in two groups of twenty-one patients, each with chronic or recurrent urinary tract infections. Both treatments lasted 10 days. At the first follow-up, 3-11 days after the end of treatment, bacteriological failure was observed in two Rifaprim patients and in four contrimoxazole patients. Clinical improvement with sterile urine or markedly reduced bacterial count was observed in nineteen. Rifaprim patients and in fifteen cases of the other group. Mild allergic phenomena were observed in three Rifaprim patients, but they did not require discontinuation of treatment; anorexia was complained of by a cotrimoxazole patient. Rifaprim appears a valuable alternative in the treatment of chronic urinary tract infection, mainly because it reduces or abolishes the risk of emergence of resistance. Topics: Adult; Bacteria; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Rifampin; Sulfamethoxazole; Trimethoprim; Urinary Tract Infections | 1979 |